Evidence map›Paper›PMID 29416652›Full record

ArticleOncotarget2018

Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05).

Lode J Swinnen, Anne O'Neill, Philip H Imus, Sachin Gujar, David Schiff, Lawrence R Kleinberg, Ranjana H Advani, Erin M Dunbar, Dennis Moore, Stuart A Grossman

Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00335140 (Phase II Study of Rituximab Given in Conjunction With Standard Chemotherapy in Primary Central Nervous System), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00335140 phase2terminatednot on this map

Phase II Study of Rituximab Given in Conjunction With Standard Chemotherapy in Primary Central Nervous System (CNS) Lymphoma

TypeinterventionalSponsorEastern Cooperative Oncology GroupRan2007 to 2015Enrolled26ConditionsLymphomaArmsRituximab, Cytarabine, Dexamethasone, Leucovorin, Methotrexate
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Lode J SwinnenJohns Hopkins University, Baltimore, Maryland, USA.
Anne O'NeillDana Farber Cancer Institute, Boston, Massachusetts, USA.
Philip H ImusJohns Hopkins University, Baltimore, Maryland, USA.
Sachin GujarJohns Hopkins University, Baltimore, Maryland, USA.
David SchiffUniversity of Virginia, Charlottesville, Virginia, USA.
Lawrence R KleinbergJohns Hopkins University, Baltimore, Maryland, USA.
Ranjana H AdvaniStanford Cancer Institute, Stanford, California, USA.
Erin M DunbarUniversity of Florida, Gainesville, Florida, USA.
Dennis MooreWichita NCORP, Wichita, Kansas, USA.
Stuart A GrossmanJohns Hopkins University, Baltimore, Maryland, USA.
Johns Hopkins University · USDana-Farber Cancer Institute · USStanford Cancer InstituteUniversity of Florida · USUniversity of Virginia · USWichita Clinic · US

Funding

Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6M
Statistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO, CONSTANTINE A. GATSONIS · 2014 to 2026
$111.2M
ECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · 2015 to 2026
$41.1M
NCI NIH HHS U10 CA180794NCI NIH HHS U10 CA180820NCI NIH HHS U24 CA196172
6 · The paper itself

Abstract

backgroundTherapy of primary CNS lymphoma (PCNSL) has focused on multi-agent chemotherapy designed to cross the blood brain barrier. Rituximab has demonstrated activity in PCNSL. E1F05 is an ECOG-ACRIN multicenter phase 2 prospective trial of rituximab with high-dose methotrexate (HD-MTX)-based chemotherapy similar to the RTOG 93-10 regimen, omitting radiotherapy.

methodsImmunocompetent patients with newly diagnosed PCNSL received HD-MTX 3.5g/m2 with vincristine every two weeks for 5 doses; procarbazine for 7 days in weeks 1, 5, and 9; cytarabine 3g/m2/day IV for 2 days in weeks 11 and 14; a dexamethasone taper over 6 weeks; and rituximab 375mg/m2 IV infusion 3 times per week for weeks 1-4. Subjects with CSF involvement received intrathecal methotrexate 12mg every two weeks.

resultsTwenty-six patients were enrolled; median age was 57. Sixteen subjects (65%) completed treatment per protocol; the most common reason for discontinuation was adverse events, and 2 subjects discontinued due to progressive disease (PD). Complete response (CR) + unconfirmed CR (CRu) was 16/25 (64%), overall response rate was 20/25 (80%), and 4/25(16%) had PD as best response. Median progression free survival (PFS) was 34 months, and median overall survival has not been reached at 40 months' median follow up. Two year PFS was 63%. The most common grade 3-4 toxicities were hematologic.

conclusionThe addition of rituximab to multi-agent chemotherapy is well tolerated. Outcomes are comparable to or better than those seen in RTOG 93-10, which included RT. These and other results suggest rituximab has activity in the CNS. [ECOG-ACRIN E1F05]. CLINICAL

trial registrationNCT00335140, clinicaltrials.gov.

Indexed as

blood-brain barrierhigh-dose methotrexatePCNSLprimary CNS lymphomarituximab

Identifiers

PMID29416652
PMCPMC5787508
OpenAlexW2767345813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.